Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.

J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.

2.

Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Kraft Z, Strouss K, Sutton WF, Cleveland B, Tso FY, Polacino P, Overbaugh J, Hu SL, Stamatatos L.

J Virol. 2008 Jun;82(12):5912-21. doi: 10.1128/JVI.00389-08. Epub 2008 Apr 9.

3.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

4.

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.

Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC.

PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.

5.

Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW, Cupo A, Crispin M, Lee KK, Desaire H, Ward AB, Klasse PJ, Moore JP.

J Virol. 2015 Dec;89(23):12189-210. doi: 10.1128/JVI.01768-15. Epub 2015 Aug 26.

7.

Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.

Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U, Chen RE, Druz A, Lees CR, Narpala S, Schön A, Van Galen J, Chuang GY, Gorman J, Harned A, Pancera M, Stewart-Jones GB, Cheng C, Freire E, McDermott AB, Mascola JR, Kwong PD.

J Virol. 2015 May;89(10):5318-29. doi: 10.1128/JVI.03451-14. Epub 2015 Mar 4.

8.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

10.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

12.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

13.

Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.

Qiao ZS, Kim M, Reinhold B, Montefiori D, Wang JH, Reinherz EL.

J Biol Chem. 2005 Jun 17;280(24):23138-46. Epub 2005 Apr 15.

14.

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH.

J Virol. 2010 Apr;84(7):3270-9. doi: 10.1128/JVI.02252-09. Epub 2010 Jan 6.

15.

Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.

Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, Chen H, Ding H, Wakefield JK, Hua D, Liao HX, Kappes JC, Sodroski J, Desaire H.

J Virol. 2015 Aug;89(16):8245-57. doi: 10.1128/JVI.00628-15. Epub 2015 May 27.

16.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

17.
18.

Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.

Quinnan GV Jr, Onabajo O, Zhang P, Yan L, Mattapallil JJ, Zhang Z, Dong M, Lu M, Montefiori D, LaBranche C, Broder CC.

PLoS One. 2014 May 20;9(5):e98060. doi: 10.1371/journal.pone.0098060. eCollection 2014.

19.

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP.

J Virol. 2002 Sep;76(17):8875-89.

20.

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.

Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF.

PLoS Pathog. 2011 Sep;7(9):e1002200. doi: 10.1371/journal.ppat.1002200. Epub 2011 Sep 1.

Items per page

Supplemental Content

Write to the Help Desk